Investors
- Board of Directors
- Board Meeting
- AGM Notice
- EGM Notice
- Closure Of Trading Window
- Related Party Transactions
- Share Holding Patterns
- Quarterly Results
- Annual Report
- Annual Return
- Secretarial Compliance
- Disclosure U/r 30
- Voting Results
- Newspaper Publications
- Insider Trading Code
- Investors-2
Mail to: companysec@indswift.com[Email id of designated official for the purpose of grievance redressal]
| Unaudited Quarterly Results For the Quarter ended 30th September, 2004 | |||||
|---|---|---|---|---|---|
| PARTICULARS | QUARTER 30.09.04 | QUARTER REVIEWED 30.09.03 | HALF YEARLY 30.09.04 | HALF YEARLY REVIEWED 30.9.03 | AUDITED 31.03.2004 |
| INCOME FROM OPERATIONS | 6040.10 | 5044.89 | 11842.12 | 10064.58 | 21248.64 |
| OTHER INCOME | 24.77 | 10.83 | 36.76 | 20.44 | 178.89 |
| TOTAL INCOME | 6064.87 | 5055.72 | 11878.88 | 10085.02 | 21427.53 |
| TOTAL EXPENDITURE | 5259.73 | 4551.23 | 10464.7 | 9082.01 | 19262.84 |
| DECREASE IN STOCK IN trADE | -437.82 | -304.06 | -146.14 | -278.56 | -1884.5 |
| CONSUMPTION OF RAW MATERIAL | 4911.04 | 4181.54 | 8991.17 | 8019.05 | 18108.87 |
| COST OF SALES | 4473.22 | 3877.48 | 8845.03 | 7740.49 | 16224.37 |
| STAFF COST | 180.46 | 160.31 | 364.84 | 310.69 | 696.55 |
| OTHER EXPENSES | 606.05 | 513.44 | 1254.83 | 1030.83 | 2341.92 |
| INTEREST | 152.46 | 148.77 | 306.49 | 285.68 | 558.71 |
| DEPRECIATION | 32.59 | 22.98 | 59.21 | 45.45 | 94.99 |
| PROFIT bEFORE TAX | 620.10 | 332.74 | 1048.48 | 671.88 | 1510.99 |
| PROVISION FOR TAX | 46.51 | 26.21 | 78.64 | 51.65 | 113.32 |
| PROVISION FOR DEFFERRED TAX | 58.35 | 0.09 | 59.39 | 9.66 | 100.91 |
| INCOME TAX FOR THE PREV.YEAR | 0 | 0 | 0 | 0 | 10.75 |
| NET PROFIT | 515.24 | 306.44 | 910.45 | 610.57 | 1286.01 |
| PAID UP SHARE CAPITAL | 611.57 | 548.57 | 611.57 | 548.57 | 571.57 |
| RESERVE EXCLUDING REVULATION RESERVE | 6574.23 | ||||
| E.P.S.(Rs.) (basic) | 8.42 | 5.59 | 14.89 | 11.13 | 23.44 |
| NON PROMOTER'S SHAREHOLDING | |||||
| No. of shares | 3961295 | 2939443 | |||
| % of total holding | 64.77 | 66.88 | |||
| NOTES: | |||||
| 1. The company has entered into critical care segments of anesthesiology, oncology and surgery by creating a dedicated division called “Resurgence”. The company is also entering herbal prescription drug by creating super specialty herbal division to address diseases for which there is no allopathic cure available. The company also intends to get into high-value niche segments such as nephrology and neuropsychiatry and later into the medical devices segments, especially orthopedic and dental equipments. In years to come, the company will create total nine marketing division to address different segments and strengthen its marketing division by doubling employee strength. 2. Considering the company’s strong distributor’s network, it is in process of forging alliances with originators who are not present in India and are willing to license their products for Indian markets (supported by manufacturing strengths of group company Ind-Swift Laboratories Limited (ISLL) to supply low cost API) to make and market those products in India. On other hand company also plans to out-license its products and NDDS to domestic as well as global players. Recently the company has entered into a co-marketing deal with Lupin to launch Nitazoxanide, an anti-diarroheal drug launched for the first time in India under brand name Nizonide and Netazox respectively. 3. The company has received a US patent for New Drug Delivery System (NDDS) of a macrolide anti-biotic drug. This is the fourth product from the company stable under NDDS for patient convenience and compliance, which has earned distinction for the company. In addition to this, the company has already filed patents for two of its products based on NDDS. The R&D of the company is working on developing 12 new molecules for launching with NDDS, which are in different stage of R&D. These new products are from the high growth therapeutic segments of Cardiology, Diabetology, neurology, cancer, asthmatic etc. 4. Continuous introduction of new API molecules by ISLL have provided excellent opportunities to the company in terms of dosage contract manufacturing along with providing technical dossier for a speedy launch of their products to market. This opportunity is available for all molecules, which ISLL manufactures. 5. The company is focusing on CRAMS as a significant growth driver. The company has embarked expansion plans which includes setting up USFDA compliant dosage form facility to cater the regulated markets, setting up another new dosage form facility to cater domestic and softly regulated market, some acquisitions in health care sector and an entry into clinical research operations. 6. The Company is exclusively in the Pharmaceutical business segment. 7. The Company has received 9 complaints during the quarter under review which were duly redressed to the satisfaction of the shareholders during the same quarter and as such, there were no pending complains as on 30th September, 2004. 8. The above financial results were taken on record by the board at its meeting held on 16th October, 2004. |
|||||
| by Order of the board | |||||
| Dated: 16.10.2004 | (Gopal Munjal) | ||||
| Place: Chandigarh | Chairman | ||||